NLS Pharmaceutics GAAP EPS of -$2.16
Source: SeekingAlpha
2026-05-01 08:48:37 ET
More on NLS Pharmaceutics
Read the full article on Seeking Alpha
For further details see:
NLS Pharmaceutics GAAP EPS of -$2.16
NewcelX Ltd.
NASDAQ: NCEL
NCEL Trading
-12.25% G/L:
$3.8018 Last:
21,074 Volume:
$4.42 Open:
NCEL Latest News
April 30, 2026 08:15:00 am
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
April 20, 2026 07:37:00 am
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
April 02, 2026 08:40:00 am
Electric Innovation Initiative Opens Submissions for 2026 Electric Innovation Awards
April 01, 2026 07:21:00 am
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
NCEL Stock Data
$13,173,712
3,104,711
N/A
23
N/A
Biotechnology & Life Sciences
Healthcare
CH
Zurich
